Please login to the form below
heart failure drug
This page shows the latest heart failure drug news and features for those working in and with pharma, biotech and healthcare.
Novartis sues US government over Medicare drug price negotiation programme
The list includes Novartis’ top-selling heart-failure medicine Entresto (sacubitril/valsartan), which the company says is the only angiotensin receptor-neprilysin inhibitor currently approved by the US Food and Drug ... Administration (FDA) to treat
Latest news
-
AstraZeneca’s heart failure treatment approved for expanded use in US
Chronic heart failure is the leading cause of hospitalisation for those over the age of 65. ... Dobber added that the approval “will help patients across the full spectrum of heart failure lead healthier lives.”.
-
Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure
The announcement comes just a month after the US Food and Drug Administration declined to approve Cytokinetics' heart failure drug omecamtiv mecarbil, with the regulator requesting results from an additional clinical ... We are disappointed with this
-
FDA approves scPharmaceuticals’ on-body infusor for congestive heart failure
The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ Furoscix (furosemide injection) for the treatment of congestion due to fluid overload among adults with chronic heart failure, the company announced. ... With the approval,
-
Boehringer Ingelheim and HeartBeat.bio partner to accelerate heart disease treatments
This collaboration is an important step in advancing our high-throughput Cardioid screening platform for drug development in different indications of heart failure. ... Our aim is to radically change the drug discovery paradigm and thus significantly
-
Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure
the composite primary endpoint of cardiovascular death or hospitalisation for heart failure in adults with heart failure with preserved ejection fraction. ... The heart failure market is becoming increasingly competitive, with Jardiance’s positive
More from news
Approximately 0 fully matching, plus 84 partially matching documents found.
Latest Intelligence
-
Addressing the diversity issue in clinical trials
One such example is the heart failure drug BiDil (isosorbide dinitrate/hydralazine), which was approved by the FDA in 2005. ... BiDil was the first ever drug recommended for use only in a single racial group after it was found to reduce deaths in African-
-
Integrating patient reported outcomes into clinical trials
Drug developers have responded by putting PROs at the heart of their clinical trial designs. ... The performance of Novartis’ heart failure drug Entresto offers one example of that potential.
-
Heart failure therapy embarks on a new era
Ivabradine is thought to be the first drug to work by decreasing the heart rate as a consequence of its action on the If channel that controls the intrinsic pacemaker in ... In the 6, 500-patient SHIFT trial, for example, the drug showed a significant
-
Pharma deals during July 2013
Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Omecamtiv mecarbil is currently in phase II trials
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Case Study: Qualitative research with payers in low and middle income countries
Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
